Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA) reported positive preclinical results for NMRA-215, an oral, brain-penetrant NLRP3 inhibitor for obesity. In three diet-induced obesity mouse studies, NMRA-215 produced up to 19% weight loss as a monotherapy and up to 26% weight loss in combination with semaglutide. The company plans to initiate a Phase 1 clinical study in Q1 2026. Additional data will be presented during a virtual R&D day on October 27, 2025 with a webcast and 30-day replay.
Positive
- Monotherapy weight loss up to 19% in DIO mice
- Combination weight loss up to 26% with semaglutide
- Phase 1 start planned in Q1 2026
Negative
- Results are limited to preclinical DIO mouse studies; human safety and efficacy are unknown
News Market Reaction 12 Alerts
On the day this news was published, NMRA gained 2.28%, reflecting a moderate positive market reaction. Argus tracked a peak move of +34.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $436M at that time.
Data tracked by StockTitan Argus on the day of publication.
NMRA-215 demonstrated class-leading weight loss of up to
NMRA-215 demonstrated best-in-class weight loss of up to
Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215
Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to
“We are very encouraged by the results of the DIO studies with NMRA-215, which validate its potential as a class-leading, novel, brain-penetrant, oral NLRP3 inhibitor for obesity,” said Paul Berns, co-founder, chief executive officer and chairman, Neumora. “These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens. These data reinforce our conviction that NMRA-215 may be an effective, next-generation, oral treatment for obesity, both as a monotherapy as well as in combination with a GLP-1 agonist. We are looking forward to moving this program into the clinic in the first quarter of 2026.”
Neumora will present additional data during its virtual R&D day on October 27, 2025 at 8:00am ET.
Webcast Information
Neumora will host a virtual R&D day at 8:00 a.m. ET on Monday, October 27, 2025. Participants can register for the live webcast here. In addition, the live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About NMRA-215
NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity. The NLRP3 inflammasome is a critical part of the innate immune system that responds to pathogens and cellular damage and is implicated in both CNS and peripheral system disorders. NLRP3-mediated neuroinflammation in the hypothalamus is lined to obesity, and targeting NLRP3 in the hypothalamus is hypothesized to modulate dysfunctional neuronal circuitry related to appetite, leading to decreased food intake. Neumora is also exploring the potential of a NMRA-215 inhibitor program for the treatment of Parkinson’s disease.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing, progress and plans for its therapeutic development programs, including the NMRA-215 studies, best-in-class pharmacology and the potential of NLRP3 inhibitors in obesity; the potential for Neumora to continue to advance NMRA-215; the potential benefits of NMRA-215; intellectual property protection and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including contract research organizations; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 which was filed with the SEC on August 6, 2025. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
What weight loss did NMRA-215 achieve in the October 27, 2025 preclinical announcement for NMRA?
When does Neumora plan to start the Phase 1 study for NMRA-215 (NMRA)?
How was NMRA-215 administered in the reported studies for NMRA on October 27, 2025?
Does the October 27, 2025 release show human trial results for NMRA-215 (NMRA)?
Will Neumora present more NMRA-215 data and where can investors watch?
